Announced details
Store-opening investments, DX and AI-related investments, specialty pharmaceutical dispensing, new businesses, digitalization of logistics and head-office functions, M&A, and overseas business expansion
GIC Private Limited is the prospective allottee of the new shares, establishing a capital relationship. The Company plans to enter into a total subscription agreement after the notification under the Financial Instruments and Exchange Act becomes effective.
A global institutional investor headquartered in Singapore. Established on 22 May 1981. It has more than 2,300 employees across 11 major financial cities worldwide and invests in more than 40 countries. Its representative is Shin Horie (Managing Director, Head of Japan Office, Representative Director). Head office: 168 Robinson Road, #37-01 Capital Tower, Singapore 068912.
5,082,000 new shares
¥3,195 per share
The disclosure states that the Company aims to achieve sustainable growth and enhance corporate value through this fund-raising, but does not provide a specific amount for its impact on results.
The company does not address Contract Value.
| Item | Details |
|---|---|
| Counterparty | GIC Private Limited |
| Counterparty overview | A global institutional investor headquartered in Singapore. Established on 22 May 1981. It has more than 2,300 employees across 11 major financial cities worldwide and invests in more than 40 countries. Its representative is Shin Horie (Managing Director, Head of Japan Office, Representative Director). Head office: 168 Robinson Road, #37-01 Capital Tower, Singapore 068912. |
| Relationship with the Company | GIC Private Limited is the prospective allottee of the new shares, establishing a capital relationship. The Company plans to enter into a total subscription agreement after the notification under the Financial Instruments and Exchange Act becomes effective. |
| Offering price | ¥3,195 per share |
| Contract Date | 9 July 2026 (the date of the Board of Directors’ resolution on the third-party allotment). The total subscription agreement is scheduled to be executed after the notification becomes effective. |
| Applicable area | Store-opening investments, DX and AI-related investments, specialty pharmaceutical dispensing, new businesses, digitalization of logistics and head-office functions, M&A, and overseas business expansion |
| Location scale | 5,082,000 new shares |
| Impact on Business Performance | The disclosure states that the Company aims to achieve sustainable growth and enhance corporate value through this fund-raising, but does not provide a specific amount for its impact on results. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To secure funding for growth investments under the new medium-term management plan, including store openings, DX and AI-related investments, specialty pharmaceutical dispensing, new businesses, and the digitalization of logistics and head-office functions; enhance the Company’s capacity to pursue large-scale M&A; and welcome a global institutional investor as a shareholder to support overseas expansion and enhance corporate value.